The center has been set up with the aim of making genomics based diagnostics effective, accessible and affordable. Triesta Sciences is a unit of HCG (HealthCare Global).

Dr B S Ajaikumar, founder & chairman , HCG Enterprise, said "We will now incorporate genomic testing which is personalized and will be the future of cancer care. This will help oncologists in clinical decisions and help our patients receive targeted individualized therapies that will improve diagnosis and prognosis of cancer."

He further added, "Through this partnership between Triesta Sciences and Strand Life Sciences we hope to enhance the work done by multi- disciplinary team of eminent and established oncologists. With this HCG joins a select group of advanced cancer care centers."

Strand-Triesta will enable the world's largest adoption of genomics-based tumor profiling for HCG patients. HCG will lead the way by adopting the Strand-Triesta advanced cancer diagnostics as a new standard that defines the future of cancer care.

Sequencing of tumor using next generation sequencing (NGS) technologies, and thorough analysis of individual patient's DNA variations will help physicians go beyond a 'one-size -fits-all' model of cancer therapy.

Such personalized approaches will improve response rates and effectiveness of targeted, chemo- and radiation therapies. Further, genomic tests can detect hereditary risk in family members of cancer patients.

Talking about this partnership, Dr Vijay Chandru, chairman & CEO, Strand Life Sciences said, "Strand is committed to expanding clinical genomics as a new paradigm for clinical decision support. The coming together of HCG, Triesta and Strand will result in achieving a scale of adoption of genomic testing, which is unprecedented even in the West."

He concluded by saying, "This scale enables affordability, but more importantly, the more cancer genomes we profile, the deeper the insights about cancer we gain. Deeper insights lead to informed decisions in cancer care."